APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live Attenuated Vaccine for Chickenpox

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Live Attenuated Vaccine for Chickenpox Market Analysis and Forecast 2026-2032

30 December 2025198 pages

Choose your research edition.

Industry ResearchLive Attenuated Vaccine for Chickenpox Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Attenuated Vaccine for Chickenpox Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Live Attenuated Vaccine for Chickenpox Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Attenuated Vaccine for Chickenpox Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Attenuated Vaccine for Chickenpox Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Live Attenuated Vaccine for Chickenpox market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Live Attenuated Vaccine for Chickenpox is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Live Attenuated Vaccine for Chickenpox is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Live Attenuated Vaccine for Chickenpox is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Live Attenuated Vaccine for Chickenpox is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Live Attenuated Vaccine for Chickenpox include GSK, BCHT, Biken, Green Cross, Keygen, Merck & Co lnc, Sanofi Pasteur, Beijing Institute of Biological Products Co., Ltd and Chengdu Institute of Biological Products Co., Ltd, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Live Attenuated Vaccine for Chickenpox, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Live Attenuated Vaccine for Chickenpox, also provides the sales of main regions and countries. Of the upcoming market potential for Live Attenuated Vaccine for Chickenpox, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Live Attenuated Vaccine for Chickenpox sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Live Attenuated Vaccine for Chickenpox market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Live Attenuated Vaccine for Chickenpox sales, projected growth trends, production technology, application and end-user industry.

Live Attenuated Vaccine for Chickenpox Segment by Company

GSK

BCHT

Biken

Green Cross

Keygen

Merck & Co lnc

Sanofi Pasteur

Beijing Institute of Biological Products Co., Ltd

Chengdu Institute of Biological Products Co., Ltd

Kexing (Dalian) Vaccine Technology Co., Ltd

Shanghai Rongsheng Biopharmaceutical Co., Ltd

Shanghai Institute of Biological Products Co., Ltd

Changchun Baike Biotechnology Co., Ltd

Changchun Qijian Biological Products Co., Ltd

Live Attenuated Vaccine for Chickenpox Segment by Type

Child

Adult

Live Attenuated Vaccine for Chickenpox Segment by Application

Hospital

Clinic

Live Attenuated Vaccine for Chickenpox Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Vaccine for Chickenpox market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Vaccine for Chickenpox and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Vaccine for Chickenpox.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Live Attenuated Vaccine for Chickenpox in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Live Attenuated Vaccine for Chickenpox manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Live Attenuated Vaccine for Chickenpox sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Live Attenuated Vaccine for Chickenpox Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Child Major Manufacturers Table 3. Adult Major Manufacturers Table 4. Global Live Attenuated Vaccine for Chickenpox Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Manufacturers Table 6. Clinic Major Manufacturers Table 7. Live Attenuated Vaccine for Chickenpox Industry Trends Table 8. Live Attenuated Vaccine for Chickenpox Industry Drivers Table 9. Live Attenuated Vaccine for Chickenpox Industry Opportunities and Challenges Table 10. Live Attenuated Vaccine for Chickenpox Industry Restraints Table 11. Global Live Attenuated Vaccine for Chickenpox Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Live Attenuated Vaccine for Chickenpox Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Live Attenuated Vaccine for Chickenpox Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region (2021-2026) Table 15. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region (2027-2032) Table 16. Global Live Attenuated Vaccine for Chickenpox Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 17. Global Live Attenuated Vaccine for Chickenpox Sales by Region (2021-2026) & (K Units) Table 18. Global Live Attenuated Vaccine for Chickenpox Sales by Region (2027-2032) & (K Units) Table 19. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Region (2021-2026) Table 20. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Region (2027-2032) Table 21. Global Live Attenuated Vaccine for Chickenpox Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Live Attenuated Vaccine for Chickenpox Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Manufacturers (2021-2026) Table 25. Global Live Attenuated Vaccine for Chickenpox Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 26. Global Live Attenuated Vaccine for Chickenpox Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Live Attenuated Vaccine for Chickenpox Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Live Attenuated Vaccine for Chickenpox Manufacturers, Product Type & Application Table 29. Global Live Attenuated Vaccine for Chickenpox Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Live Attenuated Vaccine for Chickenpox by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Live Attenuated Vaccine for Chickenpox Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type (2021-2026) Table 36. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type (2027-2032) Table 37. Global Live Attenuated Vaccine for Chickenpox Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 38. Global Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2026) & (K Units) Table 39. Global Live Attenuated Vaccine for Chickenpox Sales by Type (2027-2032) & (K Units) Table 40. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2021-2026) Table 41. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2027-2032) Table 42. Global Live Attenuated Vaccine for Chickenpox Price by Type (2021-2026) & (US$/Unit) Table 43. Global Live Attenuated Vaccine for Chickenpox Price by Type (2027-2032) & (US$/Unit) Table 44. Global Live Attenuated Vaccine for Chickenpox Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application (2021-2026) Table 48. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application (2027-2032) Table 49. Global Live Attenuated Vaccine for Chickenpox Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 50. Global Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2026) & (K Units) Table 51. Global Live Attenuated Vaccine for Chickenpox Sales by Application (2027-2032) & (K Units) Table 52. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2021-2026) Table 53. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2027-2032) Table 54. Global Live Attenuated Vaccine for Chickenpox Price by Application (2021-2026) & (US$/Unit) Table 55. Global Live Attenuated Vaccine for Chickenpox Price by Application (2027-2032) & (US$/Unit) Table 56. GSK Company Information Table 57. GSK Business Overview Table 58. GSK Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 59. GSK Live Attenuated Vaccine for Chickenpox Product Portfolio Table 60. GSK Recent Development Table 61. BCHT Company Information Table 62. BCHT Business Overview Table 63. BCHT Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. BCHT Live Attenuated Vaccine for Chickenpox Product Portfolio Table 65. BCHT Recent Development Table 66. Biken Company Information Table 67. Biken Business Overview Table 68. Biken Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Biken Live Attenuated Vaccine for Chickenpox Product Portfolio Table 70. Biken Recent Development Table 71. Green Cross Company Information Table 72. Green Cross Business Overview Table 73. Green Cross Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Green Cross Live Attenuated Vaccine for Chickenpox Product Portfolio Table 75. Green Cross Recent Development Table 76. Keygen Company Information Table 77. Keygen Business Overview Table 78. Keygen Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Keygen Live Attenuated Vaccine for Chickenpox Product Portfolio Table 80. Keygen Recent Development Table 81. Merck & Co lnc Company Information Table 82. Merck & Co lnc Business Overview Table 83. Merck & Co lnc Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Merck & Co lnc Live Attenuated Vaccine for Chickenpox Product Portfolio Table 85. Merck & Co lnc Recent Development Table 86. Sanofi Pasteur Company Information Table 87. Sanofi Pasteur Business Overview Table 88. Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Product Portfolio Table 90. Sanofi Pasteur Recent Development Table 91. Beijing Institute of Biological Products Co., Ltd Company Information Table 92. Beijing Institute of Biological Products Co., Ltd Business Overview Table 93. Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 95. Beijing Institute of Biological Products Co., Ltd Recent Development Table 96. Chengdu Institute of Biological Products Co., Ltd Company Information Table 97. Chengdu Institute of Biological Products Co., Ltd Business Overview Table 98. Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 100. Chengdu Institute of Biological Products Co., Ltd Recent Development Table 101. Kexing (Dalian) Vaccine Technology Co., Ltd Company Information Table 102. Kexing (Dalian) Vaccine Technology Co., Ltd Business Overview Table 103. Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 105. Kexing (Dalian) Vaccine Technology Co., Ltd Recent Development Table 106. Shanghai Rongsheng Biopharmaceutical Co., Ltd Company Information Table 107. Shanghai Rongsheng Biopharmaceutical Co., Ltd Business Overview Table 108. Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 110. Shanghai Rongsheng Biopharmaceutical Co., Ltd Recent Development Table 111. Shanghai Institute of Biological Products Co., Ltd Company Information Table 112. Shanghai Institute of Biological Products Co., Ltd Business Overview Table 113. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 115. Shanghai Institute of Biological Products Co., Ltd Recent Development Table 116. Changchun Baike Biotechnology Co., Ltd Company Information Table 117. Changchun Baike Biotechnology Co., Ltd Business Overview Table 118. Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 120. Changchun Baike Biotechnology Co., Ltd Recent Development Table 121. Changchun Qijian Biological Products Co., Ltd Company Information Table 122. Changchun Qijian Biological Products Co., Ltd Business Overview Table 123. Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 125. Changchun Qijian Biological Products Co., Ltd Recent Development Table 126. North America Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2026) & (US$ Million) Table 127. North America Live Attenuated Vaccine for Chickenpox Revenue by Type (2027-2032) & (US$ Million) Table 128. North America Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2026) & (K Units) Table 129. North America Live Attenuated Vaccine for Chickenpox Sales by Type (2027-2032) & (K Units) Table 130. North America Live Attenuated Vaccine for Chickenpox Sales Price by Type (2021-2026) & (US$/Unit) Table 131. North America Live Attenuated Vaccine for Chickenpox Sales Price by Type (2027-2032) & (US$/Unit) Table 132. North America Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2026) & (US$ Million) Table 133. North America Live Attenuated Vaccine for Chickenpox Revenue by Application (2027-2032) & (US$ Million) Table 134. North America Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2026) & (K Units) Table 135. North America Live Attenuated Vaccine for Chickenpox Sales by Application (2027-2032) & (K Units) Table 136. North America Live Attenuated Vaccine for Chickenpox Sales Price by Application (2021-2026) & (US$/Unit) Table 137. North America Live Attenuated Vaccine for Chickenpox Sales Price by Application (2027-2032) & (US$/Unit) Table 138. North America Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. North America Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 140. North America Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 141. North America Live Attenuated Vaccine for Chickenpox Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 142. North America Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2026) & (K Units) Table 143. North America Live Attenuated Vaccine for Chickenpox Sales by Country (2027-2032) & (K Units) Table 144. North America Live Attenuated Vaccine for Chickenpox Sales Price by Country (2021-2026) & (US$/Unit) Table 145. North America Live Attenuated Vaccine for Chickenpox Sales Price by Country (2027-2032) & (US$/Unit) Table 146. United States Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 147. Canada Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 148. Europe Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2026) & (US$ Million) Table 149. Europe Live Attenuated Vaccine for Chickenpox Revenue by Type (2027-2032) & (US$ Million) Table 150. Europe Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2026) & (K Units) Table 151. Europe Live Attenuated Vaccine for Chickenpox Sales by Type (2027-2032) & (K Units) Table 152. Europe Live Attenuated Vaccine for Chickenpox Sales Price by Type (2021-2026) & (US$/Unit) Table 153. Europe Live Attenuated Vaccine for Chickenpox Sales Price by Type (2027-2032) & (US$/Unit) Table 154. Europe Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2026) & (US$ Million) Table 155. Europe Live Attenuated Vaccine for Chickenpox Revenue by Application (2027-2032) & (US$ Million) Table 156. Europe Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2026) & (K Units) Table 157. Europe Live Attenuated Vaccine for Chickenpox Sales by Application (2027-2032) & (K Units) Table 158. Europe Live Attenuated Vaccine for Chickenpox Sales Price by Application (2021-2026) & (US$/Unit) Table 159. Europe Live Attenuated Vaccine for Chickenpox Sales Price by Application (2027-2032) & (US$/Unit) Table 160. Europe Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 161. Europe Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 162. Europe Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 163. Europe Live Attenuated Vaccine for Chickenpox Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 164. Europe Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2026) & (K Units) Table 165. Europe Live Attenuated Vaccine for Chickenpox Sales by Country (2027-2032) & (K Units) Table 166. Europe Live Attenuated Vaccine for Chickenpox Sales Price by Country (2021-2026) & (US$/Unit) Table 167. Europe Live Attenuated Vaccine for Chickenpox Sales Price by Country (2027-2032) & (US$/Unit) Table 168. Germany Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 169. France Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 170. U.K. Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 171. Italy Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 172. Netherlands Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 173. China Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2026) & (US$ Million) Table 174. China Live Attenuated Vaccine for Chickenpox Revenue by Type (2027-2032) & (US$ Million) Table 175. China Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2026) & (K Units) Table 176. China Live Attenuated Vaccine for Chickenpox Sales by Type (2027-2032) & (K Units) Table 177. China Live Attenuated Vaccine for Chickenpox Sales Price by Type (2021-2026) & (US$/Unit) Table 178. China Live Attenuated Vaccine for Chickenpox Sales Price by Type (2027-2032) & (US$/Unit) Table 179. China Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2026) & (US$ Million) Table 180. China Live Attenuated Vaccine for Chickenpox Revenue by Application (2027-2032) & (US$ Million) Table 181. China Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2026) & (K Units) Table 182. China Live Attenuated Vaccine for Chickenpox Sales by Application (2027-2032) & (K Units) Table 183. China Live Attenuated Vaccine for Chickenpox Sales Price by Application (2021-2026) & (US$/Unit) Table 184. China Live Attenuated Vaccine for Chickenpox Sales Price by Application (2027-2032) & (US$/Unit) Table 185. Asia Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2026) & (US$ Million) Table 186. Asia Live Attenuated Vaccine for Chickenpox Revenue by Type (2027-2032) & (US$ Million) Table 187. Asia Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2026) & (K Units) Table 188. Asia Live Attenuated Vaccine for Chickenpox Sales by Type (2027-2032) & (K Units) Table 189. Asia Live Attenuated Vaccine for Chickenpox Sales Price by Type (2021-2026) & (US$/Unit) Table 190. Asia Live Attenuated Vaccine for Chickenpox Sales Price by Type (2027-2032) & (US$/Unit) Table 191. Asia Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2026) & (US$ Million) Table 192. Asia Live Attenuated Vaccine for Chickenpox Revenue by Application (2027-2032) & (US$ Million) Table 193. Asia Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2026) & (K Units) Table 194. Asia Live Attenuated Vaccine for Chickenpox Sales by Application (2027-2032) & (K Units) Table 195. Asia Live Attenuated Vaccine for Chickenpox Sales Price by Application (2021-2026) & (US$/Unit) Table 196. Asia Live Attenuated Vaccine for Chickenpox Sales Price by Application (2027-2032) & (US$/Unit) Table 197. Asia Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 198. Asia Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 199. Asia Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 200. Asia Live Attenuated Vaccine for Chickenpox Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 201. Asia Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2026) & (K Units) Table 202. Asia Live Attenuated Vaccine for Chickenpox Sales by Country (2027-2032) & (K Units) Table 203. Asia Live Attenuated Vaccine for Chickenpox Sales Price by Country (2021-2026) & (US$/Unit) Table 204. Asia Live Attenuated Vaccine for Chickenpox Sales Price by Country (2027-2032) & (US$/Unit) Table 205. Japan Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 206. South Korea Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 207. India Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 208. Australia Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 209. China Taiwan Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 210. Southeast Asia Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 211. SAMEA Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2026) & (US$ Million) Table 212. SAMEA Live Attenuated Vaccine for Chickenpox Revenue by Type (2027-2032) & (US$ Million) Table 213. SAMEA Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2026) & (K Units) Table 214. SAMEA Live Attenuated Vaccine for Chickenpox Sales by Type (2027-2032) & (K Units) Table 215. SAMEA Live Attenuated Vaccine for Chickenpox Sales Price by Type (2021-2026) & (US$/Unit) Table 216. SAMEA Live Attenuated Vaccine for Chickenpox Sales Price by Type (2027-2032) & (US$/Unit) Table 217. SAMEA Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2026) & (US$ Million) Table 218. SAMEA Live Attenuated Vaccine for Chickenpox Revenue by Application (2027-2032) & (US$ Million) Table 219. SAMEA Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2026) & (K Units) Table 220. SAMEA Live Attenuated Vaccine for Chickenpox Sales by Application (2027-2032) & (K Units) Table 221. SAMEA Live Attenuated Vaccine for Chickenpox Sales Price by Application (2021-2026) & (US$/Unit) Table 222. SAMEA Live Attenuated Vaccine for Chickenpox Sales Price by Application (2027-2032) & (US$/Unit) Table 223. SAMEA Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 224. SAMEA Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 225. SAMEA Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 226. SAMEA Live Attenuated Vaccine for Chickenpox Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 227. SAMEA Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2026) & (K Units) Table 228. SAMEA Live Attenuated Vaccine for Chickenpox Sales by Country (2027-2032) & (K Units) Table 229. SAMEA Live Attenuated Vaccine for Chickenpox Sales Price by Country (2021-2026) & (US$/Unit) Table 230. SAMEA Live Attenuated Vaccine for Chickenpox Sales Price by Country (2027-2032) & (US$/Unit) Table 231. Brazil Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 232. Argentina Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 233. Chile Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 234. Colombia Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 235. Peru Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 236. Saudi Arabia Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 237. Israel Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 238. UAE Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 239. Turkey Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 240. Iran Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 241. Egypt Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Table 242. Key Raw Materials Table 243. Raw Materials Key Suppliers Table 244. Live Attenuated Vaccine for Chickenpox Distributors List Table 245. Live Attenuated Vaccine for Chickenpox Customers List Table 246. Research Programs/Design for This Report Table 247. Authors List of This Report Table 248. Secondary Sources Table 249. Primary Sources List of Figures Figure 1. Live Attenuated Vaccine for Chickenpox Image Figure 2. Global Live Attenuated Vaccine for Chickenpox Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live Attenuated Vaccine for Chickenpox Market Size Share 2021 VS 2025 VS 2032 Figure 4. Child Image Figure 5. Adult Image Figure 6. Global Live Attenuated Vaccine for Chickenpox Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Live Attenuated Vaccine for Chickenpox Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Global Live Attenuated Vaccine for Chickenpox Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Live Attenuated Vaccine for Chickenpox Revenue (2021-2032) & (US$ Million) Figure 12. Global Live Attenuated Vaccine for Chickenpox Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region (2021-2032) Figure 15. Global Live Attenuated Vaccine for Chickenpox Sales (2021-2032) & (K Units) Figure 16. Global Live Attenuated Vaccine for Chickenpox Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 17. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Live Attenuated Vaccine for Chickenpox Sales YoY (2021-2032) & (K Units) Figure 19. Europe Live Attenuated Vaccine for Chickenpox Sales YoY (2021-2032) & (K Units) Figure 20. China Live Attenuated Vaccine for Chickenpox Sales YoY (2021-2032) & (K Units) Figure 21. Asia (Excluding China) Live Attenuated Vaccine for Chickenpox Sales YoY (2021-2032) & (K Units) Figure 22. South America, Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales YoY (2021-2032) & (K Units) Figure 23. Global Live Attenuated Vaccine for Chickenpox Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Live Attenuated Vaccine for Chickenpox Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type (2021-2032) Figure 29. Global Live Attenuated Vaccine for Chickenpox Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 30. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2021-2032) Figure 32. Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application (2021-2032) Figure 35. Global Live Attenuated Vaccine for Chickenpox Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 36. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2021-2032) Figure 38. North America Live Attenuated Vaccine for Chickenpox Revenue Share by Type (2021-2032) Figure 39. North America Live Attenuated Vaccine for Chickenpox Sales Share by Type (2021-2032) Figure 40. North America Live Attenuated Vaccine for Chickenpox Revenue Share by Application (2021-2032) Figure 41. North America Live Attenuated Vaccine for Chickenpox Sales Share by Application (2021-2032) Figure 42. North America Live Attenuated Vaccine for Chickenpox Revenue Share by Country (2021-2032) Figure 43. North America Live Attenuated Vaccine for Chickenpox Sales Share by Country (2021-2032) Figure 44. Europe Live Attenuated Vaccine for Chickenpox Revenue Share by Type (2021-2032) Figure 45. Europe Live Attenuated Vaccine for Chickenpox Sales Share by Type (2021-2032) Figure 46. Europe Live Attenuated Vaccine for Chickenpox Revenue Share by Application (2021-2032) Figure 47. Europe Live Attenuated Vaccine for Chickenpox Sales Share by Application (2021-2032) Figure 48. Europe Live Attenuated Vaccine for Chickenpox Revenue Share by Country (2021-2032) Figure 49. Europe Live Attenuated Vaccine for Chickenpox Sales Share by Country (2021-2032) Figure 50. China Live Attenuated Vaccine for Chickenpox Revenue Share by Type (2021-2032) Figure 51. China Live Attenuated Vaccine for Chickenpox Sales Share by Type (2021-2032) Figure 52. China Live Attenuated Vaccine for Chickenpox Revenue Share by Application (2021-2032) Figure 53. China Live Attenuated Vaccine for Chickenpox Sales Share by Application (2021-2032) Figure 54. Asia Live Attenuated Vaccine for Chickenpox Revenue Share by Type (2021-2032) Figure 55. Asia Live Attenuated Vaccine for Chickenpox Sales Share by Type (2021-2032) Figure 56. Asia Live Attenuated Vaccine for Chickenpox Revenue Share by Application (2021-2032) Figure 57. Asia Live Attenuated Vaccine for Chickenpox Sales Share by Application (2021-2032) Figure 58. Asia Live Attenuated Vaccine for Chickenpox Revenue Share by Country (2021-2032) Figure 59. Asia Live Attenuated Vaccine for Chickenpox Sales Share by Country (2021-2032) Figure 60. SAMEA Live Attenuated Vaccine for Chickenpox Revenue Share by Type (2021-2032) Figure 61. SAMEA Live Attenuated Vaccine for Chickenpox Sales Share by Type (2021-2032) Figure 62. SAMEA Live Attenuated Vaccine for Chickenpox Revenue Share by Application (2021-2032) Figure 63. SAMEA Live Attenuated Vaccine for Chickenpox Sales Share by Application (2021-2032) Figure 64. SAMEA Live Attenuated Vaccine for Chickenpox Revenue Share by Country (2021-2032) Figure 65. SAMEA Live Attenuated Vaccine for Chickenpox Sales Share by Country (2021-2032) Figure 66. Live Attenuated Vaccine for Chickenpox Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Live Attenuated Vaccine for Chickenpox Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Child
  • Adult
Applications
  • Hospital
  • Clinic
Companies covered
  • GSK
  • BCHT
  • Biken
  • Green Cross
  • Keygen
  • Merck & Co lnc
  • Sanofi Pasteur
  • Beijing Institute of Biological Products Co., Ltd
  • Chengdu Institute of Biological Products Co., Ltd
  • Kexing (Dalian) Vaccine Technology Co., Ltd
  • Shanghai Rongsheng Biopharmaceutical Co., Ltd
  • Shanghai Institute of Biological Products Co., Ltd
  • Changchun Baike Biotechnology Co., Ltd
  • Changchun Qijian Biological Products Co., Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Live Attenuated Vaccine for Chickenpox Market by Type
  3. 1.2.1 Global Live Attenuated Vaccine for Chickenpox Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Child
  5. 1.2.3 Adult
  6. 1.3 Live Attenuated Vaccine for Chickenpox Market by Application
  7. 1.3.1 Global Live Attenuated Vaccine for Chickenpox Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Live Attenuated Vaccine for Chickenpox Market Dynamics
  1. 2.1 Live Attenuated Vaccine for Chickenpox Industry Trends
  2. 2.2 Live Attenuated Vaccine for Chickenpox Industry Drivers
  3. 2.3 Live Attenuated Vaccine for Chickenpox Industry Opportunities and Challenges
  4. 2.4 Live Attenuated Vaccine for Chickenpox Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Live Attenuated Vaccine for Chickenpox Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Region
  3. 3.2.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Region (2021-2026)
  5. 3.2.3 Global Live Attenuated Vaccine for Chickenpox Revenue by Region (2027-2032)
  6. 3.2.4 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Live Attenuated Vaccine for Chickenpox Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Live Attenuated Vaccine for Chickenpox Sales by Region
  9. 3.4.1 Global Live Attenuated Vaccine for Chickenpox Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Live Attenuated Vaccine for Chickenpox Sales by Region (2021-2026)
  11. 3.4.3 Global Live Attenuated Vaccine for Chickenpox Sales by Region (2027-2032)
  12. 3.4.4 Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Manufacturers
  2. 4.1.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Live Attenuated Vaccine for Chickenpox Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Live Attenuated Vaccine for Chickenpox Sales by Manufacturers
  6. 4.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Live Attenuated Vaccine for Chickenpox Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Live Attenuated Vaccine for Chickenpox Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Live Attenuated Vaccine for Chickenpox Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Live Attenuated Vaccine for Chickenpox Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Live Attenuated Vaccine for Chickenpox Manufacturers, Product Type & Application
  13. 4.7 Global Live Attenuated Vaccine for Chickenpox Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Live Attenuated Vaccine for Chickenpox Market CR5 and HHI
  16. 4.8.2 2025 Live Attenuated Vaccine for Chickenpox Tier 1, Tier 2, and Tier 3
5 Live Attenuated Vaccine for Chickenpox Market by Type
  1. 5.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Type
  2. 5.1.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Live Attenuated Vaccine for Chickenpox Sales by Type
  6. 5.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2021-2032)
  9. 5.3 Global Live Attenuated Vaccine for Chickenpox Price by Type
6 Live Attenuated Vaccine for Chickenpox Market by Application
  1. 6.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Application
  2. 6.1.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Live Attenuated Vaccine for Chickenpox Sales by Application
  6. 6.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2021-2032)
  9. 6.3 Global Live Attenuated Vaccine for Chickenpox Price by Application
7 Company Profiles
  1. 7.1 GSK
  2. 7.1.1 GSK Company Information
  3. 7.1.2 GSK Business Overview
  4. 7.1.3 GSK Live Attenuated Vaccine for Chickenpox Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 GSK Live Attenuated Vaccine for Chickenpox Product Portfolio
  6. 7.1.5 GSK Recent Developments
  7. 7.2 BCHT
  8. 7.2.1 BCHT Company Information
  9. 7.2.2 BCHT Business Overview
  10. 7.2.3 BCHT Live Attenuated Vaccine for Chickenpox Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 BCHT Live Attenuated Vaccine for Chickenpox Product Portfolio
  12. 7.2.5 BCHT Recent Developments
  13. 7.3 Biken
  14. 7.3.1 Biken Company Information
  15. 7.3.2 Biken Business Overview
  16. 7.3.3 Biken Live Attenuated Vaccine for Chickenpox Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Biken Live Attenuated Vaccine for Chickenpox Product Portfolio
  18. 7.3.5 Biken Recent Developments
  19. 7.4 Green Cross
  20. 7.4.1 Green Cross Company Information
  21. 7.4.2 Green Cross Business Overview
  22. 7.4.3 Green Cross Live Attenuated Vaccine for Chickenpox Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Green Cross Live Attenuated Vaccine for Chickenpox Product Portfolio
  24. 7.4.5 Green Cross Recent Developments
  25. 7.5 Keygen
  26. 7.5.1 Keygen Company Information
  27. 7.5.2 Keygen Business Overview
  28. 7.5.3 Keygen Live Attenuated Vaccine for Chickenpox Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Keygen Live Attenuated Vaccine for Chickenpox Product Portfolio
  30. 7.5.5 Keygen Recent Developments
  31. 7.6 Merck & Co lnc
  32. 7.6.1 Merck & Co lnc Company Information
  33. 7.6.2 Merck & Co lnc Business Overview
  34. 7.6.3 Merck & Co lnc Live Attenuated Vaccine for Chickenpox Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Merck & Co lnc Live Attenuated Vaccine for Chickenpox Product Portfolio
  36. 7.6.5 Merck & Co lnc Recent Developments
  37. 7.7 Sanofi Pasteur
  38. 7.7.1 Sanofi Pasteur Company Information
  39. 7.7.2 Sanofi Pasteur Business Overview
  40. 7.7.3 Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Product Portfolio
  42. 7.7.5 Sanofi Pasteur Recent Developments
  43. 7.8 Beijing Institute of Biological Products Co., Ltd
  44. 7.8.1 Beijing Institute of Biological Products Co., Ltd Company Information
  45. 7.8.2 Beijing Institute of Biological Products Co., Ltd Business Overview
  46. 7.8.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  48. 7.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
  49. 7.9 Chengdu Institute of Biological Products Co., Ltd
  50. 7.9.1 Chengdu Institute of Biological Products Co., Ltd Company Information
  51. 7.9.2 Chengdu Institute of Biological Products Co., Ltd Business Overview
  52. 7.9.3 Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  54. 7.9.5 Chengdu Institute of Biological Products Co., Ltd Recent Developments
  55. 7.10 Kexing (Dalian) Vaccine Technology Co., Ltd
  56. 7.10.1 Kexing (Dalian) Vaccine Technology Co., Ltd Company Information
  57. 7.10.2 Kexing (Dalian) Vaccine Technology Co., Ltd Business Overview
  58. 7.10.3 Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  60. 7.10.5 Kexing (Dalian) Vaccine Technology Co., Ltd Recent Developments
  61. 7.11 Shanghai Rongsheng Biopharmaceutical Co., Ltd
  62. 7.11.1 Shanghai Rongsheng Biopharmaceutical Co., Ltd Company Information
  63. 7.11.2 Shanghai Rongsheng Biopharmaceutical Co., Ltd Business Overview
  64. 7.11.3 Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  66. 7.11.5 Shanghai Rongsheng Biopharmaceutical Co., Ltd Recent Developments
  67. 7.12 Shanghai Institute of Biological Products Co., Ltd
  68. 7.12.1 Shanghai Institute of Biological Products Co., Ltd Company Information
  69. 7.12.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
  70. 7.12.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  72. 7.12.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
  73. 7.13 Changchun Baike Biotechnology Co., Ltd
  74. 7.13.1 Changchun Baike Biotechnology Co., Ltd Company Information
  75. 7.13.2 Changchun Baike Biotechnology Co., Ltd Business Overview
  76. 7.13.3 Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  78. 7.13.5 Changchun Baike Biotechnology Co., Ltd Recent Developments
  79. 7.14 Changchun Qijian Biological Products Co., Ltd
  80. 7.14.1 Changchun Qijian Biological Products Co., Ltd Company Information
  81. 7.14.2 Changchun Qijian Biological Products Co., Ltd Business Overview
  82. 7.14.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  84. 7.14.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
8 North America
  1. 8.1 North America Live Attenuated Vaccine for Chickenpox Market Size by Type
  2. 8.1.1 North America Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2032)
  3. 8.1.2 North America Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2032)
  4. 8.1.3 North America Live Attenuated Vaccine for Chickenpox Price by Type (2021-2032)
  5. 8.2 North America Live Attenuated Vaccine for Chickenpox Market Size by Application
  6. 8.2.1 North America Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2032)
  7. 8.2.2 North America Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2032)
  8. 8.2.3 North America Live Attenuated Vaccine for Chickenpox Price by Application (2021-2032)
  9. 8.3 North America Live Attenuated Vaccine for Chickenpox Market Size by Country
  10. 8.3.1 North America Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Live Attenuated Vaccine for Chickenpox Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Live Attenuated Vaccine for Chickenpox Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Live Attenuated Vaccine for Chickenpox Market Size by Type
  2. 9.1.1 Europe Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2032)
  3. 9.1.2 Europe Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2032)
  4. 9.1.3 Europe Live Attenuated Vaccine for Chickenpox Price by Type (2021-2032)
  5. 9.2 Europe Live Attenuated Vaccine for Chickenpox Market Size by Application
  6. 9.2.1 Europe Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2032)
  7. 9.2.2 Europe Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2032)
  8. 9.2.3 Europe Live Attenuated Vaccine for Chickenpox Price by Application (2021-2032)
  9. 9.3 Europe Live Attenuated Vaccine for Chickenpox Market Size by Country
  10. 9.3.1 Europe Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Live Attenuated Vaccine for Chickenpox Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Live Attenuated Vaccine for Chickenpox Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Live Attenuated Vaccine for Chickenpox Market Size by Type
  2. 10.1.1 China Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2032)
  3. 10.1.2 China Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2032)
  4. 10.1.3 China Live Attenuated Vaccine for Chickenpox Price by Type (2021-2032)
  5. 10.2 China Live Attenuated Vaccine for Chickenpox Market Size by Application
  6. 10.2.1 China Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2032)
  7. 10.2.2 China Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2032)
  8. 10.2.3 China Live Attenuated Vaccine for Chickenpox Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Live Attenuated Vaccine for Chickenpox Market Size by Type
  2. 11.1.1 Asia Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2032)
  3. 11.1.2 Asia Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2032)
  4. 11.1.3 Asia Live Attenuated Vaccine for Chickenpox Price by Type (2021-2032)
  5. 11.2 Asia Live Attenuated Vaccine for Chickenpox Market Size by Application
  6. 11.2.1 Asia Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2032)
  7. 11.2.2 Asia Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2032)
  8. 11.2.3 Asia Live Attenuated Vaccine for Chickenpox Price by Application (2021-2032)
  9. 11.3 Asia Live Attenuated Vaccine for Chickenpox Market Size by Country
  10. 11.3.1 Asia Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Live Attenuated Vaccine for Chickenpox Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Live Attenuated Vaccine for Chickenpox Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Live Attenuated Vaccine for Chickenpox Market Size by Type
  2. 12.1.1 SAMEA Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Live Attenuated Vaccine for Chickenpox Price by Type (2021-2032)
  5. 12.2 SAMEA Live Attenuated Vaccine for Chickenpox Market Size by Application
  6. 12.2.1 SAMEA Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Live Attenuated Vaccine for Chickenpox Price by Application (2021-2032)
  9. 12.3 SAMEA Live Attenuated Vaccine for Chickenpox Market Size by Country
  10. 12.3.1 SAMEA Live Attenuated Vaccine for Chickenpox Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Live Attenuated Vaccine for Chickenpox Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Live Attenuated Vaccine for Chickenpox Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Live Attenuated Vaccine for Chickenpox Value Chain Analysis
  2. 13.1.1 Live Attenuated Vaccine for Chickenpox Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Live Attenuated Vaccine for Chickenpox Production Mode & Process
  6. 13.2 Live Attenuated Vaccine for Chickenpox Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Live Attenuated Vaccine for Chickenpox Distributors
  9. 13.2.3 Live Attenuated Vaccine for Chickenpox Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst